Research article · 15 Apr 2026
Conference abstractPublished 22 Feb 2024
Women, trauma and alcohol dependency: Connections and disconnections in alcohol treatment for women
Deanna L Mulvihill,,TLI Foundation, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Globally, chronic kidney disease (CKD) is becoming more common and is closely linked to incident cardiovascular disease (CVD). The great majority of CKD patients suffer from hypertension, which can both cause and result from the disease. In people with CKD, controlling hypertension is crucial since it lowers the risk of CVD and slows the disease’s course. There is no agreement on the ideal blood pressure (BP) targets provided by current guidelines. Consequently, when deciding how to care specific patients, it is essential to comprehend the evidence that was utilised to develop these guidelines. In CKD, non-pharmacological therapies can help lower blood pressure, but they are rarely enough to achieve optimal blood pressure control. It is common for patients with chronic kidney disease (CKD) and hypertension to need a mix of antihypertensive drugs to reach goal blood pressure. When starting therapy, it is important to take into account the additional BP-independent renoprotective and/or cardioprotective activity that some pharmaceutical treatments offer. Additional difficulties arise when managing hypertension during hemodialysis and after kidney donation. In the near future, novel therapies might improve care. Importantly, meeting BP goals, lowering the risk of CVD, and delaying the progression of CKD all depend on an evidencebased, customised management plan.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Dr.Niharika”
